First International Bank & Trust Boosts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

First International Bank & Trust boosted its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 104.2% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 4,406 shares of the company’s stock after buying an additional 2,248 shares during the period. Johnson & Johnson comprises 0.3% of First International Bank & Trust’s holdings, making the stock its 27th biggest position. First International Bank & Trust’s holdings in Johnson & Johnson were worth $720,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. RKL Wealth Management LLC lifted its position in Johnson & Johnson by 2.1% during the second quarter. RKL Wealth Management LLC now owns 48,233 shares of the company’s stock valued at $8,562,000 after purchasing an additional 1,010 shares during the last quarter. Geller Advisors LLC lifted its position in Johnson & Johnson by 7.5% during the second quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock valued at $1,644,000 after purchasing an additional 648 shares during the last quarter. Simon Quick Advisors LLC lifted its position in Johnson & Johnson by 296.9% during the second quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock valued at $1,495,000 after purchasing an additional 6,537 shares during the last quarter. Lokken Investment Group LLC lifted its position in Johnson & Johnson by 1.6% during the second quarter. Lokken Investment Group LLC now owns 12,968 shares of the company’s stock valued at $2,302,000 after purchasing an additional 201 shares during the last quarter. Finally, Keebeck Alpha LP lifted its position in Johnson & Johnson by 13.4% during the second quarter. Keebeck Alpha LP now owns 4,442 shares of the company’s stock valued at $788,000 after purchasing an additional 525 shares during the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.3 %

Shares of JNJ opened at $168.31 on Tuesday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The firm has a market capitalization of $440.04 billion, a price-to-earnings ratio of 23.44, a PEG ratio of 3.21 and a beta of 0.56. The company has a 50-day moving average of $176.07 and a 200 day moving average of $171.13. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is 62.95%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the transaction, the chief financial officer now owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the transaction, the chief financial officer now owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jennifer L. Taubert sold 76,923 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the completion of the transaction, the executive vice president now directly owns 126,456 shares in the company, valued at approximately $22,354,891.68. The disclosure for this sale can be found here. In the last quarter, insiders have sold 233,611 shares of company stock valued at $40,960,735. Company insiders own 0.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Credit Suisse Group assumed coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 target price for the company. Bank of America lowered their target price on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Atlantic Securities lowered their target price on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. Barclays assumed coverage on shares of Johnson & Johnson in a report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 target price for the company. Finally, Citigroup raised their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a report on Monday, December 12th. Seven research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $181.75.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.